Clinical Trial Update: A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for niraparib (MK-4827) in participants with advanced solid tumors or hematologic malignancies, sponsored by Tesaro, Inc.; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• T-cell Prolymphocytic Leukemia

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: Tesaro, Inc. | Conditions: Solid Tumors, Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED